US breast implant firms in public attack over product standards and procedures:
This article was originally published in Clinica
Five women's groups seeking to block silicone breast implants from entering the US market have shifted their attention to reports that Mentor hid data from the FDA about product defects. The groups base their claim on a recent story in the New York Times, which detailed a 2003 court deposition of two former Mentor employees.
You may also be interested in...
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.
C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.